Skip to main content
Premium Trial:

Request an Annual Quote

Neurodegenerative Disease Testing Firm CND Life Sciences Closes $2.4M Seed Financing Round

NEW YORK – Neurodegenerative disease test development firm CND Life Sciences said on Tuesday it has closed a $2.4 million seed financing round.

HonorHealth, a local health system in the Phoenix area, and other investors participated in the funding, CND said. The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test for diagnosing neurological disorders such as Parkinson's disease and dementia with Lewy bodies, CND CEO Richard Morello said in a statement.

The Syn-One Test identifies an abnormal form of a protein called alpha-synuclein to diagnose a family of diseases known as synucleinopathies. Alpha-synucleins accumulate in nerve cells, causing a decline in neurological functions, and the Syn-One Test detects folded phosphorylated alpha-synucleins in dermal layers of the skin. The test was launched in 2019 and has been ordered by more than 100 neurologists, Phoenix-based CND said.

It announced in October a $2.4 million grant from the US National Institutes of Health to support the clinical development of the test.